skip to Main Content

dr. Kedhi Elvin

Gebruik de knoppen om de artikels, publicaties en presentaties van deze auteur te raadplegen.

Geen resultaten gevonden

Left Ventricular End-Systolic Dimension and Outcome in Patients With Heart Failure Undergoing Percutaneous MitraClip Valve Repair for Secondary Mitral Regurgitation.

Am J Cardiol. 2020 Jul 1;126:56-65.

Entrapment of dissection flap and intimal tissue cleavage during rotational atherectomy.

Cardiovasc Interv Ther. 2019 Apr;34(2):178-179. doi: 10.1007/s12928-018-0524-y. Epub 2018 Apr 26. No abstract available.

Trends in cardiovascular and bleeding outcomes in acute coronary syndrome patients treated with or without proton-pump inhibitors during the introduction of novel P2Y12 inhibitors: a five-year experience from a single-centre observational registry.

Eur Heart J Cardiovasc Pharmacother. 2019 Jul 1;5(3):127-138. doi: 10.1093/ehjcvp/pvy030.

Impact of increasing dose of intracoronary adenosine on peak hyperemia duration during fractional flow reserve assessment.

Int J Cardiol. 2019 Jun 1;284:16-21. doi: 10.1016/j.ijcard.2018.09.088. Epub 2018 Oct 2. PMID: 30293665

Timing of revascularization in patients with transient ST-segment elevation myocardial infarction: a randomized clinical trial.

Eur Heart J. 2019 Jan 14;40(3):283-291. doi: 10.1093/eurheartj/ehy651. PMID: 30371767

Impact of immature platelet fraction on platelet reactivity during prasugrel maintenance treatment.

Platelets. 2019;30(7):915-922. doi: 10.1080/09537104.2018.1535707. Epub 2018 Nov 13. PMID: 30422043

Use, timing and outcome of coronary angiography in patients with high-risk non-ST-segment elevation acute coronary syndrome in daily clinical practice: insights from a ‘real world’ prospective registry.

Neth Heart J. 2019 Feb;27(2):73-80. doi: 10.1007/s12471-018-1212-3. PMID: 30547413

A randomised, investigator-initiated, clinical trial of the effects of fentanyl on P2Y12-receptor inhibition in patients with ST-elevation myocardial infarction who are pre-treated with crushed ticagrelor: rationale and design of the Opioids aNd crushed Ticagrelor In Myocardial infarction Evaluation (ON-TIME 3) trial.

Neth Heart J. 2019 Apr;27(4):185-190. doi: 10.1007/s12471-019-1241-6. PMID: 30767166

Everolimus-eluting bioresorbable scaffolds for treatment of coronary artery disease in patients with diabetes mellitus: the midterm follow-up of the prospective ABSORB DM Benelux study.

Cardiovasc Diabetol. 2019 Mar 9;18(1):25. doi: 10.1186/s12933-019-0827-z. PMID: 30851731

Ticagrelor in the prevention of coronary and non-coronary atherothrombotic events: A comprehensive meta-analysis of 10 randomized trials.

Atherosclerosis. 2019 May;284:136-147. doi: 10.1016/j.atherosclerosis.2019.02.011. Epub 2019 Feb 25. PMID: 30884417

Impact of aging on platelet reactivity in diabetic patients receiving dual antiplatelet therapy.

J Thromb Thrombolysis. 2019 Oct;48(3):413-421. doi: 10.1007/s11239-019-01873-2. PMID: 31065927

Impact of elevated HbA1c on long-term mortality in patients presenting with acute myocardial infarction in daily clinical practice: insights from a ‘real world’ prospective registry of the Zwolle Myocardial Infarction Study Group.

Eur Heart J Acute Cardiovasc Care. 2019 May 24:2048872619849921. doi: 10.1177/2048872619849921. PMID: 31124695

Vitamin D levels and platelet reactivity in diabetic patients receiving dual antiplatelet therapy.

Vascul Pharmacol. 2019 Sep;120:106564. doi: 10.1016/j.vph.2019.106564. Epub 2019 Jun 7. PMID: 31176855

The 1 year safety and efficacy outcomes of Absorb bioresorbable vascular scaffolds for coronary artery disease treatment in diabetes mellitus patients: the ABSORB DM Benelux study.

Neth Heart J. 2019 Nov;27(11):541-549. doi: 10.1007/s12471-019-1293-7. PMID: 31197750

Rationale and design of the Onyx ONE global randomized trial: A randomized controlled trial of high-bleeding risk patients after stent placement with 1 month of dual antiplatelet therapy.

Am Heart J. 2019 Aug;214:134-141. doi: 10.1016/j.ahj.2019.04.017. Epub 2019 May 6. PMID: 31203158

Resolute zotarolimus-eluting stent in ST-elevation myocardial infarction (resolute-STEMI): A prespecified prospective register from the DAPT-STEMI trial.

Catheter Cardiovasc Interv. 2019 Jul 3. doi: 10.1002/ccd.28376. PMID: 31268629

Final results of the Randomised Evaluation of short-term DUal antiplatelet therapy in patients with acute Coronary syndromE treated with a new generation stent (REDUCE) trial.

EuroIntervention. 2019 Aug 20. pii: EIJ-D-19-00539. doi: 10.4244/EIJ-D-19-00539. PMID: 31422929

1-Year Outcomes of Delayed Versus Immediate Intervention in Patients With Transient ST-Segment Elevation Myocardial Infarction.

JACC Cardiovasc Interv. 2019 Nov 25;12(22):2272-2282. doi: 10.1016/j.jcin.2019.07.018. Epub 2019 Sep 2. PMID: 31488353

Short-term stent coverage of second-generation zotarolimus-eluting durable polymer stents: Onyx one-month optical coherence tomography study.

Postepy Kardiol Interwencyjnej. 2019;15(2):143-150. doi: 10.5114/aic.2019.86009. Epub 2019 Jun 26. PMID: 31497046

Polymer free vs polymer-coated drug-eluting stents for the treatment of coronary artery disease: A meta-analysis of 16 randomized trials.

Cardiovasc Revasc Med. 2019 Oct 23. pii: S1553-8389(19)30670-0. doi: 10.1016/j.carrev.2019.10.017. PMID: 31669109

Poly (l-lactic acid) bioresorbable scaffolds versus metallic drug-eluting stents for the treatment of coronary artery disease: A meta-analysis of 11 randomized trials.

Catheter Cardiovasc Interv. 2019 Nov 15. doi: 10.1002/ccd.28594. PMID: 31730255

Treatment of Functional Mitral Regurgitation in Heart Failure.

Curr Cardiol Rep. 2019 Nov 16;21(11):139. doi: 10.1007/s11886-019-1221-x. Review. PMID: 31734930
Geen resultaten gevonden
Back To Top